Charles P. Hart
Plus aucun poste en cours
Profil
Charles P.
Hart worked as a Director of Drug Discovery at Signature BioScience, Inc. in 2001, and as a Director of Research Unit at Affymax, Inc. from 1990 to 2000.
He also worked as a Senior Director of Biology at Galileo Pharmaceuticals, Inc. in 2004, and as a Vice President of Biology at Threshold Pharmaceuticals, Inc. from 2004 to 2015.
Hart received his graduate degree from Stanford University, his doctorate from Yale University, and his undergraduate degree from the University of California, Berkeley.
Anciens postes connus de Charles P. Hart
Sociétés | Poste | Fin |
---|---|---|
Galileo Pharmaceuticals, Inc.
Galileo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Galileo Pharmaceuticals, Inc. develops therapeutics and pharmaceuticals for redox failure such as stroke, heart attack, and diabetes. It also owns and operates laboratories. The company was founded by Dr. Guy Miller in 1998 and is headquartered in Santa Clara, CA. | Corporate Officer/Principal | 01/01/2004 |
Signature BioScience, Inc.
Signature BioScience, Inc. Miscellaneous Commercial ServicesCommercial Services Signature BioScience, Inc. discovers new drugs by applying its parallel target and compound selection process. The private company is based in Hayward, CA and has subsidiaries in the United States. The company was founded by Andrew Peter Sandham and John Hefti. | Corporate Officer/Principal | 01/01/2001 |
AFFYMAX, INC. | Corporate Officer/Principal | 01/01/2000 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Corporate Officer/Principal | - |
Formation de Charles P. Hart
University of California, Berkeley | Undergraduate Degree |
Stanford University | Graduate Degree |
Yale University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
AFFYMAX, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
Galileo Pharmaceuticals, Inc.
Galileo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Galileo Pharmaceuticals, Inc. develops therapeutics and pharmaceuticals for redox failure such as stroke, heart attack, and diabetes. It also owns and operates laboratories. The company was founded by Dr. Guy Miller in 1998 and is headquartered in Santa Clara, CA. | Health Technology |
Signature BioScience, Inc.
Signature BioScience, Inc. Miscellaneous Commercial ServicesCommercial Services Signature BioScience, Inc. discovers new drugs by applying its parallel target and compound selection process. The private company is based in Hayward, CA and has subsidiaries in the United States. The company was founded by Andrew Peter Sandham and John Hefti. | Commercial Services |